Shares of coronavirus vaccine hopefuls Moderna, Novavax, and Dynavax Technologies tumbled by double-digit percentages in August, according to data provided by S&P Global market Intelligence.
Moderna's shares were down 12.4% for the month, while Novavax and Dynavax notched steeper declines of 22.9% and 26.3%, respectively, as the race to develop the first approved vaccine heated up. Despite August's losses, Moderna's shares are still up a healthy 220% for the year. Meanwhile, Novavax's shares have risen a jaw-dropping 2,230% year to date.
While Dynavax's shares started the year strong as well -- doubling in price between Jan. 1 and July 20 -- it's since lost all of those gains and then some; its stock price is now down almost 15% for the year.